%D8%AA%D9%88%D8%A8%D8%B1%D8%A7%D9%85%D9%8A%D8%B3%D9%8A%D9%86%D8%AA%D9%88%D8%A8%D8%B1%D8%A7%D9%85%D8%A7%DB%8C%D8%B3%DB%8C%D9%86TobramicinaTobramycinTobramycinTobramicina%D8%AA%D9%88%D8%A8%D8%B1%D8%A7%D9%85%D8%A7%DB%8C%D8%B3%DB%8C%D9%86TobramysiiniTobramycineTobramicina%D7%98%D7%95%D7%91%D7%A8%D7%9E%D7%99%D7%A6%D7%99%D7%9FTobramicinaTobramycineTobramycynaTobramicinaTobramicin%C4%83%D0%A2%D0%BE%D0%B1%D1%80%D0%B0%D0%BC%D0%B8%D1%86%D0%B8%D0%BDTobramicinTobramicinTobramicinTobramycin%E0%B9%82%E0%B8%97%E0%B8%9A%E0%B8%A3%E0%B8%B2%E0%B8%A1%E0%B8%B1%E0%B8%A2%E0%B8%8B%E0%B8%B4%E0%B8%99%D0%A2%D0%BE%D0%B1%D1%80%D0%B0%D0%BC%D1%96%D1%86%D0%B8%D0%BDTobramycinQ1758380%E5%A6%A5%E5%B8%83%E9%9C%89%E7%B4%A0
about
sameAs
A Pilot Study of Tomographic Optical Breast Imaging (DBT-TOBI) to Monitor Response to Neoadjuvant TherapyPharmacokinetic Evaluation of an 8 -Week Treatment With Inhaled TobramycinTobramycin Administered by eFlow Rapid Nebulizer: Pharmacokinetic StudyPediatric Zylet Safety and Efficacy StudyZylet vs TobraDex in BlepharokeratoconjunctivitisA Bioequivalence Study of Tobradex AFKetorolac Plus Tobramycin/Dexamethasone Versus Tobramycin/Dexamethasone After Uneventful Phacoemulsification SurgerySecond Open Label Extension to Bridging Study CTBM100C2303Indirect Comparison of Tobramycin Solution for Inhalation Versus Aztreonam Lysine for Inhalation in the Treatment of Cystic FibrosisEfficacy of Zylet vs. Lotemax for the Treatment of Ocular Surface Inflammation/MGD/BlepharitisLevo-Dexa vs. Tobra+Dexa for Prevention and Treatment of Inflammation and Prevention of Infection in Cataract SurgerySafety and Efficacy in Patients Treated for Hip or Knee PJI With Vancomycin and Tobramycin Joint IrrigationTobramycin in Bronchiectasis Colonized With Pseudmonas AeruginosaEvaluation of Clinical and Microbial Efficacy and Safety of AzaSite Compared to Tobramycin for Bacterial Conjunctivitis (C-01-401-004)DPI-Tobra-Kind Cyclops® in Children With Cystic FibrosisEvaluation of Short Antibiotic Combination Courses Followed by Aerosols in Cystic FibrosisEfficacy of Over the Counter (OTC) Povidone-Ioldine 5% for Treatment of Acute or Chronic BlepharitisEarly-onset Ventilator-associated Pneumonia in Adults: Comparison of 8 Versus 15 Days of Antibiotic TreatmentClinical Trials to Reduce the Risk of Antimicrobial ResistanceLong Term Safety of Tobramycin Inhalation Powder in Patients With Cystic FibrosisPharmacokinetic Bioequivalence Study of Nebcinal® 150mg/3ml Administered by Aeroneb® Idehaler® Versus Tobi® 300mg/5ml Administered by Pari LC Plus® /Pulmoaid® in Patients With Cystic FibrosisStudy to Evaluate Arikayce™ in CF Patients With Chronic Pseudomonas Aeruginosa InfectionsChalazion Conservative Treatment TrialHuman Factors Study to Validate the User Interface of TOBI Podhaler Using Placebo CapsulesPhase III Randomized Study of the Inhalation of Tobramycin in Patients With Cystic FibrosisAntibiotic Elution in Total Knee ArthroplastyStudy for Antibiotic Impregnated Calcium Sulfate Beads as Prophylaxis for Surgical Site InfectionTobramycin Administered at the Beginning of DialysisLocally Applied Antibiotics for Infection Prophylaxis in Treatment of Open FracturesComparison of 2 Treatment Regimens for Eradication of P Aeruginosa Infection in Children With Cystic FibrosisArticulating Versus Static Antibiotic Loaded Spacers for the Treatment of Prosthetic Knee InfectionPharmacokinetic Bioequivalence Study of Nebcinal® 150mg/3ml Administered by Aeroneb® Idehaler® Versus Tobi® 300mg/5ml Administered by Pari LC Plus®Trial of Aeroquin Versus Tobramycin Inhalation Solution (TIS) in Cystic Fibrosis (CF) PatientsEffectiveness Comparison Between the Drugs TOBRACORT® and TOBRADEX® in Reducing the Signs and Symptoms of Acute Bacterial ConjunctivitisPharmacokinetic Study of Bramitob® Administered for Inhalation by PARI eFlow® vs PARI LC® PLUS NebulizerA Single Arm 48-Week Follow-on Safety Study to a Core Study Comparing the Efficacy and Tolerability of Tobrineb®/Actitob®/Bramitob® Versus TOBI®Ext. Long-term Safety Study in CF Patients: Single Arm TIPLoteprednol and Tobramycin Versus Tobramycin and Dexamethasone, in the Treatment of BlepharokeratoconjunctivitisPhase 3 Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alternating Therapy Regimen for the Treatment of Chronic Pseudomonas Aeruginosa Infection in Patients With CFSafety and Efficacy of Zylet vs Lotemax, Tobramycin and Vehicle in Pediatric Blepharoconjunctivitis
P4844
Involvement of an ATP-dependent protease, PA0779/AsrA, in inducing heat shock in response to tobramycin in Pseudomonas aeruginosa[Monitoring drug ototoxicity with distortion products]Gold nanoparticle-based colorimetric detection of kanamycin using a DNA aptamer.High-dose tobramycin inhibits lipopolysaccharide-induced MUC5AC production in human lung epithelial cells.In vitro activity of fusidic acid (CEM-102, sodium fusidate) against Staphylococcus aureus isolates from cystic fibrosis patients and its effect on the activities of tobramycin and amikacin against Pseudomonas aeruginosa and Burkholderia cepaciaSynthesis and antimicrobial evaluation of amphiphilic neamine derivatives.In vitro selection of RNA against kanamycin B.Aminoglycosides in cystic fibrosis: a descriptive study of current practice in Australia.Reduced mortality in cystic fibrosis patients treated with tobramycin inhalation solution.[Antimicrobial susceptibility of Pseudomonas aeruginosa clinical isolates in Murcia, Spain]Importance of DNase and alginate lyase for enhancing free and liposome encapsulated aminoglycoside activity against Pseudomonas aeruginosa.Bioavailability of tobramycin after oral delivery in FVB mice using CRL-1605 copolymer, an inhibitor of P-glycoprotein.Systemic exposure to tobramycin after local antibiotic treatment with calcium sulphate as carrier material.[Bacterial corneal ulcer treated with intrastromal antibiotic. Experimental model in vivo]Intravenous aminoglycoside usage and monitoring of patients with cystic fibrosis in Australia. What's new?Outpatient treatment of Pseudomonas aeruginosa bronchial colonization with long-term inhaled colistin, tobramycin, or both in adults without cystic fibrosis.Cationic amphiphiles increase activity of aminoglycoside antibiotic tobramycin in the presence of airway polyelectrolytes.[Detection and management of early Pseudomonas aeruginosa infection in patients with cystic fibrosis]Two nucleotide substitutions in the A-site of yeast 18S rRNA affect translation and differentiate the interaction of ribosomes with aminoglycoside antibiotics.High rate of aminoglycoside resistance among staphylococci causing prosthetic joint infection.The effects of intravenous tobramycin on renal tubular function in children with cystic fibrosis.Hydrophobic and hydrophilic yoctowells as receptors in water.Ototoxicity caused by topical administration of gentamicin versus tobramycin in rabbits.Higher tobramycin concentration and vibrating mesh technology can shorten antibiotic treatment time in cystic fibrosis.Mg2+ mimicry in the promotion of group I ribozyme activities by aminoglycoside antibiotics.Amphiphilic ion pairs of tobramycin with lipoamino acidsInteractions of With Species Frequently Associated With Cystic FibrosisAcute Tubular Necrosis Associated With High Serum Vancomycin and Tobramycin Levels After Revision of Total Knee Arthroplasty With Antibiotic-Containing Calcium Sulfate BeadsElectrochemical detection of tobramycin or gentamicin according to the European Pharmacopoeia analytical methodDetermination of tobramycin in soil by HPLC with ultrasonic-assisted extraction and solid-phase extractionIn vitro kinetics of delivery of tobramycin and ofloxacin from osmotic hydro gel expanders[Combined application of ciprofloxacin and tobramycin on mutant selective windows of ciprofloxacin against Pseudomonas aeruginosa]Interaction of amikacin and tobramycin with melanin in the presence of Cu2+ and Zn2+ ionsLung deposition of inhaled tobramycin with eFlow rapid/LC Plus jet nebuliser in healthy and cystic fibrosis subjects
P921
Q12192-90C93FDB-B7ED-47D8-BB60-F008EF71C070Q167844-E2B8D535-E638-4932-9B2A-814D08456F8FQ178194-0FCF1CAF-747A-46A2-9AC3-9A31E950AC0AQ178194-BB85DF43-2F31-41F5-9137-056C1DDD9D63Q19597369-67929A8A-08E9-4303-9FE8-2CEBFB3FE081Q221668-69F2950F-2CE9-4085-99C2-D0024D112B6BQ2622199-5F211C60-F7BF-457B-9DAA-43411048C06DQ32778-42C39D1E-3DF5-4423-8DF0-CDF4B63C5D5DQ34879-4D581D43-6CAA-41AD-BAC3-0457DF4D2F17Q7255052-DCCBD313-CCCC-476D-8F1F-22A2EE165C86Q727028-888ACC25-A83E-4978-8D19-7EA92763DA01
P2176
Q29006573-86EB3390-6154-434F-B3FD-9B0EA1389AA4Q29006630-2899483B-695C-495C-B240-69D867B5AF7FQ47521260-38F0BFC9-AAA6-4CF9-915F-E40A1CD4F277Q47522211-6AA90064-91AB-48CF-9D6E-2F7796C9DF09Q47522213-53642ED0-A972-4914-9881-B8393C2750CBQ48828297-891C3BB2-79A5-44BE-89E0-AF5E3676EDD8Q6147773-f74ceb12-494f-3ddc-0038-c282b1549f32
P3781
Q61728024-99627C34-D887-4702-A14F-AD9F65311A34Q61915536-06D14192-A2A5-4A40-950A-393AA99F1C4BQ61921934-935321A3-FD12-4DA0-AFDD-BFB0F9C4D3AFQ61921960-64FDCBFF-D404-445C-9CB6-A2BAD80A8145Q61924291-55B067F9-FBAE-4503-94DA-7E2061CA06C9Q61934770-AC9BE1ED-8C90-48EF-A353-6891A0CEF36CQ61935798-C960C396-6B1D-4A39-A17B-46F9727720F5Q61938896-81130D0B-0A7D-4712-ADFF-68D9BDB0BAEAQ61957341-499A7D46-1D3C-42E9-8B88-9906F99D0D6AQ61966028-A3E7D862-9724-4762-99FE-02ABF3F2FD18Q62035113-DA38A196-162A-41BA-9DF5-932E479D8AB7Q62039715-B408B35F-9DF8-4532-96C0-26A53D2ACCF0Q62041028-3B79CA3C-6FD4-438F-9B74-6AAC46CC8C07Q62105783-6DEB4589-2A53-49C1-A6C0-F3846CB2E876Q62809586-2262ACE1-0B25-4AEF-9677-D637273CD579Q63229449-3578C54B-011B-4AEC-9413-2D2E6EB8C226Q63316524-FA651068-BB99-4ECB-B8D9-386D06B930E7Q63316905-6B6FE31A-CF7B-4E71-BA1C-4226E9C487A7Q63316977-8284E6DB-18B2-47B4-B67A-59DF6559BE73Q63320655-7DD53CB2-B2C6-4F67-B2D5-D49E242C708DQ63335674-B05E9B09-6627-4896-93E1-F1D8237EE768Q63338287-947E555F-D4F5-49D3-9D93-8E9887F470F8Q63341153-F5C280B7-1874-4FFF-AB43-FD4077630220Q63398745-7DFDDE8E-7F78-4381-990D-54B8FAFE8C8EQ63400990-7DDFFE5A-DD41-46E5-A507-A9DE5B29D1D0Q63572061-9A649078-201D-4AAE-B005-D69CA122A347Q63572613-FA549BE6-0840-4CD1-A0C1-DDDBA5CB6B73Q63588043-30A800E0-190C-4058-B465-3EFAB33644B6Q63599706-47B7089F-1B8D-4271-B1B1-534A9C83787BQ63807332-CD8DC3D9-E52E-4A2C-8ED4-E68544BDD5DEQ63812889-80A8D1DC-EA2C-4F1B-8977-FBFE5042713BQ63814345-C3D5C6DD-2D47-48E2-9D0F-B6853F5633FCQ63815986-E99D035D-F501-4A22-89E3-A3504A71766FQ63816665-E44C3BD4-EF26-4DDA-8AAB-B2CF88A4B229Q63831602-405AE522-11C6-4D3A-BDF7-B3E965FE7F0FQ63832939-8E806F41-C88B-4889-8629-5F274323B392Q63834742-D07E3EC4-C1E6-426F-B052-54856ED75621Q63838388-C43D640B-054B-4820-B15A-1F122E9FCBFCQ64030480-95D9E40B-BD63-470D-B7C3-C2647C01A178Q64041963-F8DB301A-3A5C-4CB0-A448-97DA8022C03C
P4844
description
chemesch Verbindung
@lb
chemical compound
@en
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de
chemische Verbindung
@de-ch
chemische verbinding
@nl
name
Tobramicin
@sh
Tobramicin
@sl
Tobramicin
@sr
Tobramicin
@sr-el
Tobramicina
@gl
Tobramicina
@it
Tobramicină
@ro
Tobramycin
@de
Tobramycin
@sv
Tobramycin
@vi
type
label
Tobramicin
@sh
Tobramicin
@sl
Tobramicin
@sr
Tobramicin
@sr-el
Tobramicina
@gl
Tobramicina
@it
Tobramicină
@ro
Tobramycin
@de
Tobramycin
@sv
Tobramycin
@vi
altLabel
3'-Deoxykanamycin b
@en
32986-56-4
@fr
47663
@en
49842-07-1
@fr
79645-27-5
@fr
ATC kod J01GB01
@sr
ATCvet kod QJ01GB01
@sr
ATCvet kod QS01AA12
@sr
Aktob
@en
Bethkis
@en
prefLabel
Tobramicin
@sh
Tobramicin
@sl
Tobramicin
@sr
Tobramicin
@sr-el
Tobramicina
@gl
Tobramicina
@it
Tobramicină
@ro
Tobramycin
@de
Tobramycin
@sv
Tobramycin
@vi